Gene expression profiling to identify potentially relevant disease outcomes and support human health risk assessment for carbon black nanoparticle exposure  by Bourdon, Julie A. et al.
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a  b  s  t  r  a  c  t
New  approaches  are  urgently  needed  to evaluate  potential  hazards  posed  by  exposure  to nanomaterials.
Gene  expression  proﬁling  provides  information  on potential  modes  of action  and  human  relevance,  and
tools  have  recently  become  available  for pathway-based  quantitative  risk  assessment.  The objective  of
this study  was  to use toxicogenomics  in  the  context  of  human  health  risk  assessment.  We explore  the
utility  of  toxicogenomics  in risk assessment,  using  published  gene  expression  data  from  C57BL/6  mice
exposed  to 18,  54 and  162  g Printex  90 carbon  black  nanoparticles  (CBNP).  Analysis  of  CBNP-perturbed
pathways,  networks  and  transcription  factors  revealed  concomitant  changes  in  predicted  phenotypes
(e.g.,  pulmonary  inﬂammation  and  genotoxicity),  that  correlated  with  dose  and time.  Benchmark  doses
(BMDs) for  apical  endpoints  were  comparable  to minimum  BMDs  for relevant  pathway-speciﬁc  expres-
sion changes.  Comparison  to inﬂammatory  lung  disease  models  (i.e.,  allergic  airway  inﬂammation,
bacterial  infection  and  tissue  injury  and  ﬁbrosis)  and  human  disease  proﬁles  revealed  that  induced  gene
expression  changes  in  Printex  90  exposed  mice  were  similar  to those  typical  for  pulmonary  injury  and
ﬁbrosis.  Very  similar  ﬁbrotic  pathways  were  perturbed  in CBNP-exposed  mice  and  human  ﬁbrosis  dis-
ease models.  Our  synthesis  demonstrates  how  toxicogenomic  proﬁles  may  be used in  human  health  risk
assessment  of  nanoparticles  and  constitutes  an  important  step  forward  in the  ultimate  recognition  of  tox-
icogenomic  endpoints  in  human  health  risk.  As  our  knowledge  of  molecular  pathways,  dose–response
characteristics  and  relevance  to  human  disease  continues  to grow,  we  anticipate  that  toxicogenomics
will  become  increasingly  useful  in assessing  chemical  toxicities  and  in  human  health  risk assessment.
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. Introduction
Chronic inhalation of ﬁne and ultraﬁne particulate matter has
een associated with adverse pulmonary effects including ﬁbro-
is and cancer, as well as exacerbation of existing conditions such
s asthma, bronchitis and chronic obstructive pulmonary disorder
Bonner, 2007; Knaapen et al., 2004), in addition to cardiovascular
isease (Dockery et al., 1993; Pope et al., 2004). Human exposure to
anufactured nanomaterials (NMs), which have at least one size
imension that is less than 100 nm,  may  constitute an increased
isk of adverse effects especially following inhalation exposure, and
heir potential to induce toxic effects is poorly understood (Handy
Abbreviations: BMD, benchmark dose; BMDL, lower conﬁdence limit benchmark
ose; CBNP, carbon black nanoparticle; FDR, false-discovery rate; HHRA, human
ealth risk assessment; NM,  nanomaterial.
∗ Corresponding author. Tel.: +1 613 941 7376; fax: +1 613 941 8530.
E-mail address: Carole.Yauk@hc-sc.gc.ca (C.L. Yauk).
300-483X Crown Copyright © 2012 Pu blished by El sevie r Ireland Lt d.   
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Open access under C©  2012 Published by Elsevier Ireland Ltd. 
and Shaw, 2007). Moreover, the human health risks associated
with inhalation exposure have not been adequately investigated.
Methods that can be effective in screening for NM toxicities are
paramount, due to the countless variations in physical and chem-
ical properties of NMs  in terms of size, shape, agglomeration and
surface coatings.
Traditional assays used in human health risk assessment (HHRA)
generally involve chronic and subchronic rodent exposures with
concomitant analyses of tumour induction (e.g., two-year rodent
cancer bioassay), in addition to various non-cancer endpoints, the
most sensitive of which is used for regulatory decision-making
(Meek et al., 1994). These approaches form the foundation of
the chemical regulatory system and have been invaluable for
HHRA. However, some of these assays, such as those based on
chronic animal exposures at the maximum tolerated dose, are
Open access under CC BY-NC-ND license.time and resource intensive, thus limiting broad application (Suter
et al., 2004). Recent discussions have identiﬁed gene expression
proﬁling as a potentially rapid and cost-effective approach for iden-
tifying and assessing prospective hazard, characterizing chemical
   C BY-NC-ND license.
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or particle) mode of action, and assessing human relevance in sup-
ort of HHRA (National Academy of Sciences, 2007). In order for
ene expression data to become accepted for routine use in HHRA, it
s necessary to demonstrate that mRNA/protein expression proﬁles
an effectively predict the modes of action and biological outcomes
f exposure at relevant doses, and to conﬁrm that these data can be
sed to strengthen the foundation for HHRA and regulatory deci-
ions. In this regard, it has been hypothesized that gene expression
roﬁling will be extremely useful in identifying effects at low doses,
nd moreover, useful for distinguishing between doses that elicit
n adaptive response vs. those that yield adverse effects (Boverhof
nd Zacharewski, 2006). To date, the application of gene expression
roﬁling in regulatory toxicology has largely focused on qualita-
ive identiﬁcation of chemical modes of action and transcription
iomarkers that can predict speciﬁc toxicities. However, the util-
ty of gene expression proﬁling in quantitative determination of
hreshold values (e.g., benchmark doses) has not yet been rigor-
usly explored (Thomas et al., 2012).
In the present study we investigate the utility of gene expres-
ion proﬁles derived from mice exposed to Printex 90 carbon
lack nanoparticles (CBNPs) by intratracheal installation to iden-
ify potential hazards, modes of action, and doses above which
dverse effects may  be expected for speciﬁc toxicological out-
omes. In addition, we quantitatively compare benchmark doses
or pathways to those of apical endpoints derived from the same
xperimental animals. We  employ Printex 90 as a model NM due
o the rich database of traditional toxicity information on which
ur ﬁndings can be anchored. Brieﬂy, Printex 90 consists almost
ntirely of carbon, with very low levels of impurities in terms of
olycyclic aromatic hydrocarbons and endotoxins (Bourdon et al.,
012b; Jacobsen et al., 2008; Saber et al., 2011) They generate
eactive oxygen species (Jacobsen et al., 2008), induce DNA strand
reaks in vitro and in vivo (Jacobsen et al., 2009; Saber et al., 2005)
nd mutations in vitro (Jacobsen et al., 2007) that are associated
ith oxidative stress (Jacobsen et al., 2011). The data in this study
re from previously published experiments investigating Printex
0 CBNP exposure in C57BL/6 mice at various doses (i.e., vehicle,
8, 54 and 162 g) collected at several time-points (1, 3 and 28
ays) following a single acute instillation (Bourdon et al., 2012a).
e  previously characterized widespread changes in gene expres-
ion involving acute phase response and inﬂammation, supported
y concomitant inﬂuxes of pulmonary bronchoalveolar lavage cells
BAL) and increases in tissue-speciﬁc DNA strand breaks (Bourdon
t al., 2012a,b). In addition to the examination of BMDs and BMDLs,
e compare CBNP-modiﬁed gene expression proﬁles to various
odels of lung disease in mice and humans reported in the lit-
rature, in order to explore the utility of our data in predicting the
otential risk of adverse health outcomes and the human relevance
f expression changes. The work demonstrates one approach by
hich gene expression proﬁling may  be integrated into HHRA to
upport or predict apical toxicological endpoints, dose–response,
nd relevance to human diseases.
. Materials and methods
.1. Summary of experimental model and published results
Details of the mouse exposures, particle characterization and pulmonary pheno-
ype were previously published in Bourdon et al. (2012a,b). Brieﬂy, female C57BL/6
ice were exposed to a single installation of vehicle or Printex 90 (18, 54 or 162 g)
nd  euthanized 1, 3 and 28 days post-exposure (n = 6/group). The intratracheal instil-
ation route of exposure allows for deposition of known doses directly in the lungs of
he mice, and controls for potential dermal- and ingestion-related CBNP exposure
hat can occur during whole body inhalation exposures. The doses were selected
o  represent 1, 3 and 9 working days of exposure at the occupational inhalation
xposure limit of 3.5 mg/m3 of CB (as established by the US Occupational Safety and
ealth Administration (OSHA) and the US National Institute for Occupational Safety
nd  Health (NIOSH))) for a mouse (assuming 1.8 L/h inhalation rate and 33.8% par-
icle deposition in mouse, for an 8 h working day) (Dybing et al., 1997; Jacobsengy 303 (2013) 83– 93
et al., 2009). Very limited ﬁltration of CBNPs from the nose is expected during
human exposure. Printex 90 CBNPs were characterized and displayed the follow-
ing  properties: 14 nm primary particle size, 295–338 m2/g Brunauer Emmett and
Teller (BET) surface area, 74.2 g/g PAHs, 142 EU/g endotoxin, polydispersity index
of  1, −10.7 mV zeta potential, 2.6 m peak hydrodynamic number and 3.1 m peak
volume-size-distribution (Bourdon et al., 2012b).
Analysis of pulmonary inﬂammatory cellular inﬂux in bronchoalveolar lavage
(BAL) revealed neutrophilic inﬂammation that was sustained to day 28 at all doses.
Tissue-speciﬁc genotoxicity, as observed by DNA strand breaks, persisted up to
day  28 at the two highest doses and FPG-sensitive sites at all doses on day 1 and
the  highest dose on day 3 (Bourdon et al., 2012b). Whole mouse genome DNA
microarray revealed 487 and 81 differentially expressed genes (FDR adjusted p-
value ≤ 0.1 and fold changes ≥ 1.5) overall in lung and liver, respectively (Bourdon
et  al., 2012a). The complete microarray dataset is available through the Gene Expres-
sion Omnibus at NCBI (http://www.ncbi.nlm.nih.gov/geo/, Superseries GSE35284,
SubSeries GSE35193). This dataset was previously used to examine molecular inter-
actions between lung and liver upon CBNP exposure (Bourdon et al., 2012a).
2.2.  Rank-based pathway analysis
To determine the most affected processes of CBNP exposure, pathway analysis
of gene expression data was conducted using a rank based test in R (R Development
Core Team, 2011) as described in Alvo et al. (2010). The relative expression for the
genes in a pathway was ﬁrst aligned by subtracting the median expression value for
the combined treatment and control groups. These values were then ranked within
each subject and the vector of average ranks was calculated for each treatment
group. The distance between the two treatments was calculated and a permutation
analysis was used to obtain a p-value for each pathway. Pathways with p < 0.05 were
considered signiﬁcant.
2.3. Benchmark dose (BMD)/lower conﬁdence limit benchmark dose (BMDL)
calculation for apical endpoints and RT-PCR data
BMD10 (BMD representing an excess risk of 10% in exposed animals vs. controls)
and BMDLs (95% conﬁdence limit) were calculated for apical endpoint data (inﬂam-
mation and genotoxicity) and for RT-PCR using EPA BMDS 2.2 (Davis et al., 2011).
Only data that were statistically above control levels (p < 0.05) for at least two of
the  doses were included. Prior to running the analysis, the data were screened for
homogeneity of variance, and then ﬁt against ﬁve continuous dose–response mod-
els  (i.e., hill, polynomial, linear, power and exponential). Goodness of ﬁt >0.05 and
scaled residuals within ±2.0 was  applied as a cut off for selection of the appropriate
model, and curves were also inspected visually. When more than one model was
suitable, the one with the lowest Akaike’s information criterion (AIC) was selected.
2.4.  BMD/BMDL calculation for genomic data
In order to determine BMDs and BMDLs for gene expression data, BMDExpress
was  employed (Yang et al., 2007). Brieﬂy, microarray probes with more than one
representation on each array were averaged. Analyses were performed on genes
that were identiﬁed as statistically signiﬁcant by one-way ANOVA (p < 0.05) using
the four following models: Hill, Power, Linear 1◦ and Polynomial 2◦ . The Power
model had a power restriction of ≥1. Selection on Linear and Polynomial 2◦ was
based on choosing a model which describes the data with the least complexity. A
nested Chi-square test, with cut-off of 0.05, ﬁrst selects among linear and polyno-
mial models, followed by comparing AIC, which measures the relative goodness
of ﬁt. A Hill model was  excluded if the “k” parameter of the model was less than
1/3  of the lowest positive dose (18 g) (Black et al., 2012). Other settings included
maximum iterations of 250, conﬁdence level of 0.95, benchmark response (BMR) of
1.349 (number of standard deviation deﬁning BMD) (Yang et al., 2007). For functional
classiﬁcations and analyses, the resulting BMD  datasets were mapped to KEGG path-
ways with promiscuous probes removed (probes that mapped to multiple annotated
genes). BMDs that exceeded the highest exposure dose (162 g) and that exceeded
a  goodness-of-ﬁt p-value of 0.1 were removed from the analysis.
2.5. Prediction analysis for microarrays
To determine the correlation between gene expression proﬁles of mice exposed
to  CBNPs with those of mouse pulmonary disease models, a prediction analysis for
microarrays (PAM) (Tibshirani et al., 2002) was conducted in R (R Development
Core Team, 2011) using the PAMR library (Hastie et al., 2011). Data for this analysis
encompassed 13 mouse lung disease models, and were obtained from the National
Centre for Biotechnology Information Gene Expression Omnibus (accession
#GSE4231 and #GSE11037). The samples were labelled as belonging to one of
three models of lung inﬂammation: bacterial infection, lung injury and ﬁbrosis,
or  Th2 response (allergic airway inﬂammation). Probes with common GENBANK
accessions were collapsed to a single measurement for each sample using the
mean. Using the common accession numbers, a prediction model using shrunken
centroids was estimated. Cross-validation of the nearest shrunken centroid
classiﬁer was conducted to identify an appropriate threshold. PAMR implements
10-fold cross-validation. This involves dividing the samples into ten approximately
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qual-size parts ensuring that the classes are distributed proportionally. Ten-fold
ross-validation works by ﬁtting a model on 90% of the samples and then predicting
he class labels of the remaining 10%. This procedure is repeated ten times, with
ach  part playing the role of the test samples and the errors on all ten parts added
ogether to compute the overall error. A threshold of 2 was  selected, yielding a
lassiﬁer with 753 GENBANK accessions. The means of the nine CBNP treatment
onditions were then classiﬁed using the estimated prediction model.
.6. Functional analysis using inﬂammatory lung disease models
Functional analysis was  conducted to establish molecular perturbations that
ere in common or discrepant between CBNP exposed mice and inﬂammatory lung
isease models. The analysis was conducted on genes that were common between
BNP and each lung disease model, then again for genes that were unique to CBNP,
sing a cut-off of FDR-adjusted p < 0.1 and a fold-change > 1.5 for all datasets. The
ess stringent cut-off was  employed for disease models because of the low power
n  several of the datasets. DAVID Bioinformatics Resources 6.7 was used to identify
nriched biological functions from terms with similar genes and biological meaning
Huang et al., 2009a,b). DAVID Biological functions with enrichment scores > 1.3
ere considered signiﬁcant, in accordance with DAVID recommendations (Huang
t  al., 2009a). Clusters with enrichment scores > 1.3 in our analysis contained at least
ne  gene ontology term or pathway for which the Benjamini-corrected p-value was
0.05.
.7. Mining of public data repositories for disease prediction
In order to predict potential disease outcomes of relevance to humans, gene
xpression proﬁles were mined against genomic data repositories. Disease predic-
ion analysis was  done in NextBio (http://nextbio.com) using the high dose exposure
roﬁles as differentially expressed genes were identiﬁed at all time-points for this
ose. Data from CBNP exposed mice were compared to curated datasets to identify
isease studies with similar gene proﬁles, gene ranking and consistency. Pairwise
ene signature correlations and rank-based enrichment statistics were employed in
he calculation of NextBio scores for each disease. The disease that ranked highest
n  comparison with CBNP exposure was given a score of 100, and the rest of the
esults were normalized accordingly (Kupershmidt et al., 2010). Meta-analysis was
erformed using select disease models for mice, as well as for human studies rep-
esentative of disease state. The analysis identiﬁed, ranked and scored all genes and
iogroups that were common between the studies according to the scoring method
escribed above for disease prediction (Kupershmidt et al., 2010). Biogroups were
ltered for canonical pathways.
. Results
.1. Pathway analysis
The rank-based pathway analysis revealed a total of 151, 150
nd 106 differentially expressed KEGG pathways on days 1, 3 and
8, respectively. The most affected pathways according to statis-
ical signiﬁcance were primarily related to inﬂammation on day
, to steroid biosynthesis and DNA repair on day 3 and to apo-
tosis and inﬂammation on day 28. Signiﬁcant pathways (p < 0.05)
ertaining to genotoxicity (DNA damage and repair) and inﬂam-
atory and immune responses are summarized in Table 1, along
ith previously established phenotypes. All signiﬁcant pathways
re presented in Supplemental Table 1. Analysis of the number
f common pathways between doses for each time-point revealed
hat most pathways occurring at lower doses also occur at higher
oses. However, the number of signiﬁcant pathways increased with
ose (Fig. 1).
.2. BMD  and BMDL
EPA BMDS 2.2 BMDs and BMDLs were generated for apical
ndpoints and RT-PCR data (BMD values for each endpoint and
ene presented in Supplementary Table 2; curves are presented
n Supplemental Fig. S1).  Although many of the apical endpoints
nd RT-PCR data were not suitable for modelling, BMD  and BMDL
alues generally increased over post-exposure time as expected.
he mean BMDs for inﬂammatory apical endpoints were 0.9, 1.2
nd 9.6 g, and BMDLs were 0.6, 0.9 and 6.5 g on days 1, 3 and
8, respectively. BMD  values for RT-PCR data of genes involved in
nﬂammation tended to be higher than for apical endpoints. Meangy 303 (2013) 83– 93 85
BMDs of inﬂammatory genes were 14.5, 16.7 and 29.0 g, and mean
BMDLs were 10.4, 9.1 and 20.1 g, on days 1, 3 and 28, respectively.
BMDs and BMDLs were also generated for microarray gene
expression proﬁles using BMDExpress. Minimum BMDs  for KEGG
pathways relevant to inﬂammation, KEGG pathways relevant to
genotoxicity, for the most sensitive KEGG pathways as well as for
apical endpoint data are presented in Table 2. Minimum BMDs
were calculated according to the median of all signiﬁcant genes
for each pathway and the 5th percentile of signiﬁcant genes of
all pathways, in order to increase sensitivity. Even the 5th per-
centile BMDs tended to be higher than BMDs generated for apical
endpoints (Table 2). However, minimum BMDs, representing the
most sensitive gene for each relevant pathway, were much more
comparable to BMDs of apical endpoints (Table 2).
3.3. Prediction analysis for microarray
PAM was used to compare the Printex 90 gene expression
dataset to 13 pulmonary gene expression proﬁles that represent
a range of murine pulmonary disease models (e.g., transgene over-
expression, treatments with infectious agents, toxic chemicals and
allergens) as described in Lewis et al. (2008),  Thomson et al. (2012).
The models were classiﬁed according to the three following sub-
groups: (1) bacterial infection, (2) lung injury and ﬁbrosis, and (3)
Th2 response (allergic airway inﬂammation).
Clustering of the models using PAM is shown in Fig. 2A. Two
CBNP exposure conditions (day 28 low and medium doses) did
not cluster with other CBNP exposure condition or other disease
models, likely due to lack of response. Models of bacterial infec-
tion did not cluster with other disease models or CBNP exposure.
PAM analysis revealed an association between CBNP exposure,
Th2 responses and lung injury/ﬁbrotic responses. Although Th2
response and lung injury/ﬁbrotic responses were more closely
associated with one another than with CBNP exposure, PAM anal-
ysis revealed that CBNP exposure was more closely related to lung
injury/ﬁbrotic responses than to Th2 responses, which is also sup-
ported by probability statistics comparing CBNP exposure with
each disease sub-group (Fig. 2B).
3.4. Functional analysis
In order to examine commonalities and discrepancies between
disease models and CBNP exposure in more detail, functional analy-
sis was  conducted on (1) genes that were in common between CBNP
and each disease model and (2) genes that were unique to CBNP.
The number of signiﬁcant genes used for each analysis is presented
in Supplemental Table 3. The DAVID biological functions are sum-
marized in Table 3. This analysis demonstrates that inﬂammation
was common between most models at all time-points (excluding
Aspergillus extract). On day 1, commonalities for CBNP exposure
were observed with bacterial infection models (i.e., due to the acute
phase response) and with injury and ﬁbrosis models (i.e., due to
changes in tissue morphogenesis related genes). Day 3 revealed
inﬂammation and cell cycle disturbances in most of the models.
However, CBNP responses were more similar to bleomycin-induced
lung injury as shown by the high degree of overlapping biological
functions on day 3 (Table 3). CBNPs triggered an adaptive immune
response on day 28 that was also only apparent in lung injury and
ﬁbrosis models.
3.5. Disease predictionGene expression proﬁles from the high dose CBNP-exposed
mice vs. control were analysed in NextBio to identify closely
related respiratory disease proﬁles in humans. On all post-exposure
days, severe acute respiratory syndrome (SARS), congenital cystic
86
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Table 1
Summary of signiﬁcant KEGG pathways (p ≤ 0.05) relating to phenotypes established in Bourdon et al. (2012a,b).
Day 1 Day 3 Day 28
Genotoxicity-
related
pathways
Inﬂammation-
related
pathways
Phenotype Genotoxicity-
related
pathways
Inﬂammation-
related
pathways
Phenotype Genotoxicity-
related
pathways
Inﬂammation-
related
pathways
Phenotype
18 g Apoptosis NOD-like
receptor
signalling
DNA strand
breaks; FPG
sensitive sites;
neutrophil
inﬂux
Neutrophil
inﬂux;
eosinophil
inﬂux;
lymphocyte
inﬂux;
macrophage
inﬂux
Apoptosis Neutrophil
inﬂux
54  g Nucleotide
excision repair;
glutathione
metabolism
NOD-like
receptor
signalling;
Toll-like
receptor
signalling;
cytokine–cytokine
receptor
signalling;
antigen
processing and
presentation
DNA strand
breaks; FPG
sensitive sites;
neutrophil
inﬂux
Homologous
recombination;
base excision
repair; cell
cycle; p53
signalling;
nucleotide
excision repair;
non-
homologous
end-joining
T Cell receptor
signalling;
hematopoietic
cell lineage;
MAPK
signalling;
antigen
processing and
presentation;
Toll-like
receptor
signalling;
NOD-like
receptor
signalling;
Jak-STAT
signalling; B
cell receptor
signalling
DNA strand
breaks;
Eosinophil
inﬂux;
Lymphocyte
inﬂux
Apoptosis DNA strand
breaks;
eosinophil
inﬂux;
lymphocyte
inﬂux
162  g Glutathione
metabolism;
mismatch
repair; cell
cycle;
nucleaotide
excision repair;
homologous
recombination;
non-
homologous
end-joining;
base excision
repair; p53
signalling
NOD-like
receptor
signalling;
antigen
processing and
presentation;
cytokine–cytokine
receptor
interaction;
Toll-like
receptor
signalling; T
cell receptor
signalling;
Hematopoietic
cell lineage;
Jak-STAT
signalling;
MAPK
signalling;
chemokine
signalling; B
cell receptor
signalling
DNA strand
breaks; FPG
sensitive sites;
neutrophil
inﬂux
Homologous
recombination;
glutathione
metabolism;
cell cycle;
mismatch
repair;
nucleotide
excision repair;
base excision
repair; non-
homologous
end-joining;
p53 signalling
Antigen
processing and
presentation;
NOD-like
receptor
signalling;
hematopoietic
cell lineage;
cytokine–cytokine
receptor
interaction;
Jak-STAT
signalling;
Toll-like
receptor
signalling;
chemokine
signalling
pathway;
complement
and
coagulation
cascades
DNA strand
breaks; FPG
sensitive sites;
neutrophil
inﬂux;
eosinophil
inﬂux
Glutathione
metabolism;
non-
homologous
end-joining
NOD-like
receptor
signalling;
cytokine–cytokine
receptor
interaction;
Jak-STAT
signalling;
antigen
processing and
presentation; B
cell receptor
signalling;
Toll-like
receptor
signalling;
hematopoietic
cell lineage
DNA strand
breaks;
neutrophil
inﬂux;
lymphocyte
inﬂux
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Fig. 1. Venn diagrams illustrating overlap of signiﬁcant pathways (p < 0.05) according to dose, for each post-exposure day (1, 3 and 28 days) in C57BL/6 mice exposed to
CBNPs.
Table  2
BMD  and BMDL for apical endpoints and KEGG pathways relevant to inﬂammation and genotoxicity.
Day 1 Endpoint/pathway Day 3 Endpoint/pathway Day 28 Endpoint/pathway
Apical endpoints
Min  inﬂammation related BMD  0.5 Neutrophil inﬂux 0.6 Eosinophil inﬂux 3.7 Neutrophil inﬂux
Min  inﬂammation related BMDL 0.3 Neutrophil inﬂux 0.6 Eosinophil inﬂux 2.2 Neutrophil inﬂux
Min  genotoxicity related BMD  n/a n/a 4.5 DNA strand breaks 2.4 DNA strand breaks
Min  genotoxicity related BMDL n/a n/a 3.0 DNA strand breaks 1.6 DNA strand breaks
KEGG  pathways relevant to inﬂammation
Min  median-based BMDa 29.4 Complement and
coagulation cascades
32.8 Cytokine–cytokine
receptor interaction
77.7 MAPK signalling
pathway
Min  5th percentile-based BMDb 18.6 Toll-like receptor
signalling pathway
20.2 Hematopoietic cell
lineage
70.9 T cell receptor
signalling pathway
Mean  minimum BMDc 1.8 n/a 3.3 n/a 12.2 n/a
Min  median-based BMDLd 17.2 Antigen processing and
presentation
19.3 Cytokine–cytokine
receptor interaction
54.6 Leucocyte
transendothelial
migration
KEGG  pathways relevant to genotoxicity
Min  median-based BMDa 31.9 Apoptosis 29.4 Base excision repair 29.4 Cell cycle
min  5th percentile-based BMDb 23.6 p53 signalling pathway 6.7E-13 Non-homologous
end-joining
30.2 p53 signalling pathway
Mean  minimum BMDc 18.8 n/a 11.6 n/a 1.88E-06 n/a
Min  median-based BMDLd 18.5 Apoptosis 7.8E-06 Non-homologous
end-joining
16.5 Cell cycle
All  pathways
Min  median-based BMDa 17.2 Heparan sulfate
biosynthesis
0.7 Keratan sulfate
biosynthesis
6.21E-09 Glycine, serine and
threonine metabolism
Min  5th percentile-based BMDb 1.9E-13 Amyotrophic lateral
sclerosis (ALS)
2.98E-13 N-Glycan degradation 1.00E-01 Alkaloid biosynthesis II
Min  median-based BMDLd 2.9 Biotin metabolism 9.11E-10 Keratan sulfate
biosynthesis
6.21E-09 Glycine, serine and
threonine metabolism
a Median-based BMD  calculated for each pathway, based on individual BMDs of signiﬁcant genes.
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rb 5th percentile-based BMD  calculated for each pathway, based on individual BM
c Minimum BMD  correspond to one gene with the lowest BMD, for each pathway
d Median-based BMDL calculated for each pathway, based on individual BMDLs o
denomatoid malformation, and injury of lung, were identiﬁed as
he top three respiratory diseases associated with CBNP exposure.
nterestingly, ﬁbrosis was identiﬁed as a predicted disease outcome
f CBNP exposure that increased considerably with time (e.g., score
f 14 on day 1, 35 on day 3 and 45 on day 28). In order to examine
he molecular mechanisms that may  be involved in ﬁbrosis in more
etail, a meta-analysis was completed using curated studies within
extBio that identiﬁed ﬁbrosis as a phenotype. Meta-analysis in
ouse employed 36 models that included ﬁbrosis-induced by
njury with naphthalene, bleomycin and ganciclovir, doxycycline-
nduced over-expression, and TGF- over-expression in a variety
f mouse models (wild type, inﬂammation resistant/susceptible).
eta-analysis using CBNP gene expression proﬁles in mouse
anked 473 canonical pathways and 21,277 genes present in at leastsigniﬁcant genes.
iﬁcant genes.
one of the studies on select models of pulmonary ﬁbrosis and lung
injury (identiﬁed in NextBio disease correlation proﬁles). In order
to establish human-relevance, the analysis was repeated using
human studies curated in NextBio. Meta-analysis encompassed 4
studies from lung biopsies of patients affected with ﬁbrosis, with
intermediate to severe pulmonary hypertension, pneumonia and
exacerbation of idiopathic pulmonary ﬁbrosis. Overall, 472 canon-
ical pathways and 15,795 genes were ranked as present in at least
one of the studies.
The top ranked pathways and genes for the mouse and human
meta-analyses are presented in Table 4. Interestingly, comparison
of fold-ranks between the mouse and human analysis revealed that
the most affected pathways were the same in both species. How-
ever, the genes that were most perturbed during ﬁbrotic responses
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aig. 2. PAM using mouse gene expression proﬁles from 13 lung disease models and C
ut-off  of 2. Sample are classiﬁed according to CBNP exposure (purple), Th2 respo
robability statistics comparing CBNP exposure for each disease sub-group.
ere considerably different in CBNP-exposed mice compared
o human diseases, with the exception of glycerol-3-phosphate
ehydrogenase (GDP1), kruppel-like factor 4 (KLF4), secreted phos-
hoprotein 1 (SPP1) and ceruloplasmin (CP).
. Discussion
It is now widely accepted that toxicity is preceded by, and
ccompanied by, transcriptional changes, thus providing molecu-
ar signatures of direct and indirect toxic effects (Auerbach et al.,
010; Fielden et al., 2011; Gatzidou et al., 2007). It is hypothe-
ized that toxicogenomic proﬁling can be used as a screening tool
o prioritize the speciﬁc assays that should be conducted from
he standard battery of tests, thus minimizing animal use, cost
nd time (Dix et al., 2007). Moreover, global analyses of trans-
riptional changes provide a wealth of information that can be
sed to identify putative modes of action and to query relevance
o human adverse health outcomes (Currie, 2012). This type of
pproach is the general premise of the widely supported paradigm
utlined in ‘Toxicity Testing in the 21st Century’ (National Academy
f Sciences, 2007). However, substantive work demonstrating the
bility of gene expression proﬁles to identify hazards, to assess riskxposed mice. (A) Represents clustering of 753 genes as selected by a PAM threshold
ellow), injury and ﬁbrosis (blue) and bacterial infection (red). (B) Represents the
of exposure via quantitative dose–response analysis, and to iden-
tify adverse outcomes associated with speciﬁc modes of action is
required before these endpoints can be used in HHRA. The present
study applies pathway- and network-based approaches, BMD mod-
elling, and disease prediction tools to gene expression data to
explore the relationship between apical endpoints and transcrip-
tional proﬁles. The work investigates the potential utility of gene
expression proﬁling in determining hazard and mode of action of
NPs, in characterizing dose–response relationships and in predict-
ing the relevance of these ﬁndings to potential disease-outcomes
and human health effects for HHRA.
4.1. Hazard identiﬁcation, mode of action and prediction of apical
endpoints
The utility of gene expression proﬁling in hazard identiﬁcation
has been examined for a limited number of chemicals, including
dibutyl phthalate and acetaminophen (Euling et al., 2011; Kienhuis
et al., 2011; Makris et al., 2010). Toxicogenomic proﬁles of
alachlor exposure in rat olfactory mucosa (Genter et al., 2002) and
dimethylarsenic (DMA) exposure in human cultured bladder cells
and rat bladder epithelium (Sen et al., 2005; US EPA, 2005) have also
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Table 3
Comparison of CBNP proﬁles with lung disease models using functional analysis for genes in common (grey) and genes
unique to CBNP (black).
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Day 1
Acute Phase Response
Inflammation
Chemotaxis
Innate Immune Response
Adaptive Immune 
Response
Toll-like Response
Response to Bacterium
Cell Death
Oxidative Stress
Proliferation
Tissue Morphogenesis
Day 3
Acute Phase Response
Inflammation
Chemotaxis
Innate Immune Response
Toll-like Response
Cell Death
Cell Cycle
Oxidative Stress
Chromatin Assembly
Steroid Biosynthesis
Day 28
Inflammation
Chemotaxis
Innate Immune Response
Adaptive Immune 
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Toll-like Response
Response to Bacterium
Cell Death
Cell Cycle
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iPhagocytosis
rovided useful information for two ﬁnal assessments of acetochlor
nd arsenicals (US EPA, 2004, 2006). Our data demonstrate that
ene expression proﬁles can also be viewed as effective predictors
f the biological effects of CBNP exposure. For example, inﬂam-
atory responses manifested at the gene expression level and
etected using DNA microarrays and classiﬁed in this work using
EGG pathway analyses and previously in the same mice using
ngenuity pathway analysis (Bourdon et al., 2012a)  are entirely
onsistent with the observed pulmonary inﬂux of inﬂammatory
arkers (e.g., neutrophils, eosinophils and lymphocytes). The num-
er of genes perturbed and the magnitude of expression changes
n these pathways correlates with dose and time. In addition,
bserved transcriptomic changes associated with perturbations of
ell cycle networks, alterations of non-homologous end-joining,
nd p53 signalling support the sustained genotoxicity observed
n the mice, although dose and time correlations were not asapparent (e.g., levels of DNA strand breaks remained relatively
constant at the two highest exposure doses (Bourdon et al., 2012b)
whereas induction of DNA repair genes decreased with dose and
time). The transcriptomic changes associated with alterations in
glutathione metabolism and free radical scavenging correlate with
induction of DNA formamidopyrimidine DNA glycoslase (FPG)
sensitive sites (an indicator of oxidative DNA damage) early after
the exposure. The persistence of this response is an indication of
an adaptive response to oxidative stress in the lungs of the mice.
Interestingly, CBNP-induced alterations in gene expression proﬁles
also revealed a pulmonary acute phase response and unexpected
changes in lipid homeostasis, which were subsequently supported
by measured decreases in plasma high density lipoprotein (HDL)
(Bourdon et al., 2012a). The strong association between CBNP-
induced gene expression proﬁles and apical endpoints collectively
support the use of toxicogenomics for hazard identiﬁcation of
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Table  4
Meta-analyses in NextBio using mouse and human proﬁles in which ﬁbrosis was  a phenotype. Values in parentheses represent rank in the opposite species (mouse or human).
Rank 1 (rank 2) Pathway Rank 1 (rank 2) Gene (symbol)
Mouse
1 (1) Cytokine–cytokine receptor interaction 1 (698) Cyclin-dependent kinase inhibitor 1a (Cdkn1a)
2  (13) p53 signalling pathway 2 (158) Matrix metalloproteinase 14 (Mmp14)
3  (28) Focal adhesion 3 (2353) Tissue inhibitor of metalloporteinase 1 (Timp1)
4  (22) Cell cycle 4 (535) Metallothionein 2 (Mt2)
5  (2) Toll-like receptor signalling pathway 5 (786) Thymidine kinase 1 (Tk1)
6  (15) Cell communication 6 (2936) Osteoglycin (Ogn)
7  (29) ECM receptor interaction 7 (–) elastin (Eln)
8  (16) Cell cycle G1 to S reactome 8 (594) Suppressor of cytokine signalling 3 (Socs3)
9  (19) Cell cycle G1/S checkpoint 9 (273) Lysloxidase (Lox)
10  (3) Hematopoitic cell lineage 10 (491) Serum amyloid a3 (Saa3)
Human
1  (1) Cytokine–cytokine receptor interaction 1 (1001) Mucin 4 (MUC4)
2  (5) Toll-like receptor signalling pathway 2 (652) Glutathione S-transferase alpha 1 (GSTA1)
3  (10) Hematopoitic cell lineage 3 (56) Kruppel-like factor 4 (KLF4)
4  (17) Erythrocyte differentiation pathway 4 (4161) Golgi membrane protein 1 (GOLM1)
5  (14) IL-1R pathway 5 (48) Glycerol-3-phosphate dehydrogenase 1 (GPD1)
6  (12) Calcineurin Nf at signalling 6 (1366) Spermatogenesis associated, serine-rich 1 (SPATS2L)
7  (26) Local acute inﬂammatory response pathway 7 (76) Secreted phosphoprotein 1 (SPP1)
N
a
z
a
t
b
T
i
i
t
p
a8  (27) Cytokines and inﬂammatory pathway 
9  (21) MMP  cytokine connection 
10  (30) Msp/RON receptor signalling pathway 
Ms, and perhaps more importantly, for highlighting unexpected
dverse outcomes. Moreover, ongoing work within the Organi-
ation for Economic Co-operation and Development (OECD) is
ctively developing adverse outcome pathways (AOP) approaches
hat are expected to provide tangible methods by which systems
iology endpoints can be used in human health risk assessment.
oxicogenomics data that examine responses over dose and time
n a variety of tissues can be very useful for such applications, as
llustrated for CBNP exposure in Fig. 3. Overall, our data suggest
hat gene expression proﬁles can be effectively used to identify
utative mode(s) of action and hazards of NP exposure, in the
bsence of phenotypic data.
Fig. 3. Use of toxicogenomic data and observed p8 (620) Chemokine (C-X-C motif) ligand 10 (CXCL10)
9 (89) Ceruloplasmin (CP)
10 (–) Vanin 2 (VNN2)
4.2. Dose–response characterization
In addition to identiﬁcation of hazard, it has been suggested
that gene expression proﬁles may  be useful for quantitative assess-
ment (e.g., establishment of reference doses) of responses related
to both cancer and non-cancer endpoints (Thomas et al., 2007).
Benchmark doses are generally considered more informative than
the no observable adverse effect level (NOAEL) in deriving reference
doses as they are based on the entire dose–response relationship
(Crump et al., 1995). Because alterations in gene expression can
be initiated in the absence of biological effects (e.g., adaptive or
stress response pathways effective in mitigating toxic effects), it is
henotypes in an adverse outcome pathway.
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xpected that reference doses for genomics endpoints may  be too
ensitive for use in HHRA. However, previous analyses of 5 chem-
cals (i.e., 1,4-dichlorobenzene, propylene glycol mono-t-butyl
ther, 1,2,3-trichloropropane, methylene chloride and naphtha-
ene) showed that median BMD  and BMDLs for the most sensitive
athways and GO categories were highly correlated with BMD
nd BMDLs of cancer and non-cancer endpoints (Thomas et al.,
011, 2012).
In the current study, rather than choosing the most sensitive (i.e.,
owest) BMDs, we focussed on the analysis of pathways that were
peciﬁc to biological outcomes observed in the mice (i.e., phenotyp-
cally anchored), and calculated BMDs for these relevant genes and
athways. The pathway-based BMDs and BMDLs calculated here for
elevant pathways were actually less sensitive (i.e., higher BMDs)
han those of the observed apical endpoints. However, the mean
f the minimum BMDs and BMDLs across all the pathways that
e assigned as relevant to the apical endpoints (i.e., corresponding
o the most sensitive genes within the relevant pathways) were
imilar to those of relevant apical endpoints. Median BMDs and
MDLs for the most sensitive pathways also correlate more closely
ith apical endpoints even though the pathways were not neces-
arily relevant to these endpoints. This ﬁnding supports previous
xamples demonstrating a 1:1 correlation between BMDs for gene
xpression and apical endpoints (Thomas et al., 2011, 2012). These
ata indicate the potential utility of using gene expression pro-
les in determining acceptable exposure limits for NPs. In order to
etermine the speciﬁc utility of pathway derived BMDs in HHRA, it
ill be necessary to establish a comprehensive catalogue of path-
ays that are actually perturbed in the event of speciﬁc adverse
ffects.
.3. Disease prediction and relevance to humans
Perhaps the principal motivation for including gene expression
roﬁling in HHRA is the wealth of information that can be used
o identify key events that are correlated with adverse outcomes
hat are relevant to human disease, and moreover can be used
o predict the likelihood of a human disease. Identiﬁcation of key
vents at the transcriptional level can facilitate the identiﬁcation
f processes that are critical for disease initiation and progres-
ion, thus allowing information from animal experiments to be
ueried and used for extrapolation to human scenarios (Edwards
nd Preston, 2008). Comparison of our data with speciﬁc models
f lung disease, including bacterial infection, airway hypersen-
itivity and lung injury revealed that CBNPs induced responses
hat were more closely related to lung injury and ﬁbrosis than
o other models. This ﬁnding was further supported by compari-
on of the expression proﬁles of CBNP exposed mice to those of
urated studies of animals and humans exhibiting a myriad of pul-
onary disease phenotypes. This analysis demonstrates that CBNP
xposure perturbs genes that are known to be involved in tissue
njury and ﬁbrosis in mice. Although it is unclear if CBNP exposure
ould result in the same gene expression proﬁle in humans, sim-
lar pathways including many involved in ﬁbrotic responses were
ound in both mice and humans (52% of the top 50 pathways found
ere common between mouse and human). Despite concordance
f pathways, the top ranked genes differed considerably between
oth species. However, many of the genes found in mice and
umans had similar functions, including inﬂammatory and acute
hase responses (e.g., Saa3, Socs3 and Mt2  in mice and CP,  VNN2
nd CXCL10 in humans), cell cycle progression (Cdkn1a in mice and
LF4 in humans) and bone and tissue modelling (Mmp14, Timp1,
ln and Ogn in mice and SPP1 in humans). Thus, despite discord-
nce in the gene expression proﬁles between species, the similar
unctions of top ranked genes and concordance between pathways
upports the likelihood of similar responses in the event of CBNPgy 303 (2013) 83– 93 91
exposure in humans. In addition, ﬁbrosis has been identiﬁed as
an outcome of exposure to various particles and NPs in animals
(Bermudez et al., 2004; Shvedova et al., 2008), including Printex
90 (e.g., 28-day nose only inhalation in Wistar WU  rats) (Bellmann
et al., 2009), as well as in humans (Lkhasuren et al., 2007; Wang
and Christiani, 2003). The process of pulmonary ﬁbrosis is closely
related to progression of carcinogenic outcome (Hubbard et al.,
2000). These data demonstrating very similar ﬁbrotic pathways
in mice and humans and a signiﬁcant overlap with CBNP-induced
gene expression changes thus support the use of pathway-based
approaches in identifying molecular mechanisms of disease onset
and progression, and using gene expression proﬁles to support
HHRA.
4.4. Conclusions and recommendations
This study conﬁrms several key elements that are necessary for
the application of gene expression proﬁling for HHRA of toxicant
exposures in general. First, transcriptional proﬁles can effectively
predict the biological effects of chemical exposures. Speciﬁcally,
in the absence of data for any apical endpoints, our data would
have suggested that mice exposed to CBNPs exhibit an inﬂamma-
tory response, oxidative stress, DNA damage and perturbations in
cholesterol metabolism. Second, a comparison of BMDs  and BMDLs
of relevant pathways and apical endpoints conﬁrms that minimum
pathway BMDs and BMDLs are in the same range as those of api-
cal endpoints. Third, that expression proﬁles can be fairly easily
mined to identify potential adverse outcomes (i.e., diseases) that
are relevant to humans, and might reasonably be expected to occur
in humans exposed to substances that elicit speciﬁc gene expres-
sion patterns in experimental animals. We  believe that our work
constitutes a signiﬁcant step towards the ultimate recognition of
toxicogenomic endpoints for routine assessment of human health
risk.
Gene expression proﬁling offers a promising approach to deci-
pher the largely unknown hazards of NP exposure. Due to the
unique properties of NPs, powerful technologies that can assess
a multitude of adverse outcome possibilities will be required to
elucidate their modes of action and potential impacts on human
health within a time-frame that is suitable for prompt regula-
tory decision making. This same premise should hold true for any
new chemical products, for which toxicity is largely or completely
unknown. In order to establish a strong foundation for the integra-
tion of gene expression proﬁling into HHRA, it will be necessary
for the approach employed here to be applied to a variety of addi-
tional chemicals/particles that span a wide range of toxicological
potencies and modes of action, and using a variety of experimental
designs (e.g., multiple doses and time-points). As our knowledge
of molecular pathways, and of the diverse tools used to decipher
their biological signiﬁcance, dose–response characteristics and rel-
evance to human disease continues to grow, we anticipate that
toxicogenomics will become increasingly useful in assessing the
toxicological hazards of a wide range of test articles, and by exten-
sion, for HHRA.
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